Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases

Fabiola Atzeni, Maurizio Turiel, Ivana Hollan, Pierluigi Meroni, Simona Sitia, Livio Tomasoni, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic inflammation is an important factor in the development of atherosclerotic plaque and endothelial dysfunction. The levels of biomarkers such as serum pentraxin 3 (PTX3), an innate immunity protein, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, are higher in SRD patients with cardiovascular (CV) disease and are now recognized as new CV risk factors.Many diagnostic methods and imaging techniques detect subtle pre-clinical CV abnormalities in SRD patients, although their clinical significance has not yet been established in patients. Echocardiographic examinations based on the evaluation of coronary flow reserve (CFR), tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) seem to be the most suitable means of screening and diagnosis. Furthermore, plasma ADMA levels could be used as a simple means of screening SRD patients at higher CV risk who need more aggressive treatment aimed at slowing or reversing the progression of atherosclerosis.

Original languageEnglish
Pages (from-to)845-848
Number of pages4
JournalAutoimmunity Reviews
Volume9
Issue number12
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Rheumatic Diseases
Biomarkers
Atherosclerosis
Cardiovascular Abnormalities
Atherosclerotic Plaques
Diagnostic Imaging
Innate Immunity
Nitric Oxide Synthase
Echocardiography
Cardiovascular Diseases
Inflammation
Serum
Proteins
N,N-dimethylarginine
Therapeutics

Keywords

  • Atherosclerosis
  • Autoimmune diseases
  • Biomarkers
  • Echocardiography
  • Rheumatic diseases

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. / Atzeni, Fabiola; Turiel, Maurizio; Hollan, Ivana; Meroni, Pierluigi; Sitia, Simona; Tomasoni, Livio; Sarzi-Puttini, Piercarlo.

In: Autoimmunity Reviews, Vol. 9, No. 12, 10.2010, p. 845-848.

Research output: Contribution to journalArticle

Atzeni, Fabiola ; Turiel, Maurizio ; Hollan, Ivana ; Meroni, Pierluigi ; Sitia, Simona ; Tomasoni, Livio ; Sarzi-Puttini, Piercarlo. / Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 12. pp. 845-848.
@article{289b984df2164f1a8d909311ed75b317,
title = "Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases",
abstract = "Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic inflammation is an important factor in the development of atherosclerotic plaque and endothelial dysfunction. The levels of biomarkers such as serum pentraxin 3 (PTX3), an innate immunity protein, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, are higher in SRD patients with cardiovascular (CV) disease and are now recognized as new CV risk factors.Many diagnostic methods and imaging techniques detect subtle pre-clinical CV abnormalities in SRD patients, although their clinical significance has not yet been established in patients. Echocardiographic examinations based on the evaluation of coronary flow reserve (CFR), tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) seem to be the most suitable means of screening and diagnosis. Furthermore, plasma ADMA levels could be used as a simple means of screening SRD patients at higher CV risk who need more aggressive treatment aimed at slowing or reversing the progression of atherosclerosis.",
keywords = "Atherosclerosis, Autoimmune diseases, Biomarkers, Echocardiography, Rheumatic diseases",
author = "Fabiola Atzeni and Maurizio Turiel and Ivana Hollan and Pierluigi Meroni and Simona Sitia and Livio Tomasoni and Piercarlo Sarzi-Puttini",
year = "2010",
month = "10",
doi = "10.1016/j.autrev.2010.08.001",
language = "English",
volume = "9",
pages = "845--848",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases

AU - Atzeni, Fabiola

AU - Turiel, Maurizio

AU - Hollan, Ivana

AU - Meroni, Pierluigi

AU - Sitia, Simona

AU - Tomasoni, Livio

AU - Sarzi-Puttini, Piercarlo

PY - 2010/10

Y1 - 2010/10

N2 - Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic inflammation is an important factor in the development of atherosclerotic plaque and endothelial dysfunction. The levels of biomarkers such as serum pentraxin 3 (PTX3), an innate immunity protein, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, are higher in SRD patients with cardiovascular (CV) disease and are now recognized as new CV risk factors.Many diagnostic methods and imaging techniques detect subtle pre-clinical CV abnormalities in SRD patients, although their clinical significance has not yet been established in patients. Echocardiographic examinations based on the evaluation of coronary flow reserve (CFR), tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) seem to be the most suitable means of screening and diagnosis. Furthermore, plasma ADMA levels could be used as a simple means of screening SRD patients at higher CV risk who need more aggressive treatment aimed at slowing or reversing the progression of atherosclerosis.

AB - Systemic rheumatic diseases (SRDs) are associated with accelerated atherosclerosis. It has recently been recognised that chronic inflammation is an important factor in the development of atherosclerotic plaque and endothelial dysfunction. The levels of biomarkers such as serum pentraxin 3 (PTX3), an innate immunity protein, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, are higher in SRD patients with cardiovascular (CV) disease and are now recognized as new CV risk factors.Many diagnostic methods and imaging techniques detect subtle pre-clinical CV abnormalities in SRD patients, although their clinical significance has not yet been established in patients. Echocardiographic examinations based on the evaluation of coronary flow reserve (CFR), tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) seem to be the most suitable means of screening and diagnosis. Furthermore, plasma ADMA levels could be used as a simple means of screening SRD patients at higher CV risk who need more aggressive treatment aimed at slowing or reversing the progression of atherosclerosis.

KW - Atherosclerosis

KW - Autoimmune diseases

KW - Biomarkers

KW - Echocardiography

KW - Rheumatic diseases

UR - http://www.scopus.com/inward/record.url?scp=77956905076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956905076&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.08.001

DO - 10.1016/j.autrev.2010.08.001

M3 - Article

VL - 9

SP - 845

EP - 848

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 12

ER -